In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.
Journal in Which the Study was Published: Blood Cancer Discovery, a journal of the American Association for Cancer Research.
Authors: Michael Pulsipher, MD, a professor of pediatrics and the division chief of Pediatric Hematology and Oncology at Intermountain Primary Children’s Hospital and the Huntsman Cancer Institute of the University of Utah, and Stephan Grupp, MD, PhD, senior author of the study and a professor of pediatrics and the chief of Cell Therapy and Transplant at Children’s Hospital of Philadelphia and the University of Pennsylvania.